Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,430.66 22.12 0.13%
S&P 500 1,868.81 3.96 0.21%
NASDAQ 4,107.58 12.06 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics,



Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone
Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine)
(2012 - 2017)

Dublin, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Research and Markets
(http://www.researchandmarkets.com/research/97b65k/epigenetics) has announced
the addition of the "Epigenetics Technology Market (Epigenomics, DNA
Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics,
Personalized Medicine) (2012 - 2017)" report to their offering.

Over the last decade, genomics and proteomics have been used as key tools to
discover potential drug targets and to better understand the complexities of
biology. To balance research in these areas, epigenetics offers a potential
opportunity in understanding the basis of various diseases in a different
approach. Thus, epigenetics is study of heritable changes in genome function
and gene expression had opened the new gate of biology to understand the basis
of diseases and presents incredible opportunities for disease diagnosis and
drug discovery.

Report covers the market by therapeutics sector in oncology conditions,
non-oncology indications and personalized medicine. The report also covers the
market by research and diagnostics sector in gene regulation studies,
biomarker detection and drug discovery. In addition, it also includes the
factors driving and restraining the market and covers the market scenario in
the U.S., Europe, Asia and the Rest of the World (ROW). This report will
provide the company profiles of key companies along with the competitive
analysis.

The Global Epigenetics market is showing a double digit growth (CAGR 25%) due
to supportive factors such as, (i) huge amount of funds and investments, (ii)
increasing partnerships and collaborations, and (iii) rapid screening tools.
Epigenetics is used in the identification of new epigenetic biomarkers, which
will aid in better diagnosis and prognosis of diseases. While there are
factors favoring the market growth, there are concerns such as change in
re-imbursement systems and lack of predictive markers holding back the growth
of this market. However, the positive aspects in this field may very well
offset the market restraints to aid the market grow at an exceptional rate.

Key Topics Covered:

1. INTRODUCTION

2. EXECUTIVE SUMMARY

3. EPIGENETICS - TECHNOLOGY LANDSCAPE ANALYSIS

4. EPIGENETICS - MARKET LANDSCAPE ANALYSIS

5. TECHNOLOGY INVESTMENT POTENTIAL

5.2 INVESTMENT OPPORTUNITIES

6. EPIGENETICS - TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY

7. EPIGENETICS COMPETITIVE LANDSCAPE

8. INTELLECTUAL PROPERTY AND RESEARCH STRENGTH ANALYSIS

9. ANALYST INSIGHTS AND RECOMMENDATIONS

10. COMPANY PROFILES

11. APPENDIX

12. GLOSSARY

Companies Mentioned

  * 4SC (GERMANY)
  * CELGENE (U.S.)
  * CELLCENTRIC (U.K.)
  * CH3 BIOSYSTEMS (U.S.)
  * COVARIS INC. (U.S.)
  * EISAI CO. LTD. (JAPAN)
  * EPIONTIS (GERMANY)
  * EPITHERAPEUTICS (DENMARK)
  * EPIZYME (U.S.)
  * KARUS THERAPEUTICS (U.K.)
  * MERCK MILLIPORE (U.S.)
  * RIBOMED BIOTECHNOLOGIES (U.S.)

For more information visit
 http://www.researchandmarkets.com/research/97b65k/epigenetics

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Research and Markets logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement